Cardiovascular effects of atomoxetine in children, adolescents, and adults

Drug Safety

Volumn 26, Issue 10, 2003, Pages 729-740

  Wernicke, Joachim F ^a   Faries, Douglas ^a   Girod, Donald ^b   Brown, Jeffrey W ^a   Gao, Haitao ^a   Kelsey, Douglas ^a   Quintana, Humberto ^c   Lipetz, Robert ^d   Michelson, David ^a   Heiligenstein, John ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d Encompass Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATOMOXETINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; SCHOOL CHILD; SIDE EFFECT; STATISTICAL ANALYSIS;

EID: 0043124593     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326100-00006     Document Type: Article

References (15)

1. Michelson D, Faries DE, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108 (5): e83
2. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159 (11): 1-6
3. Spencer T, Heiligenstein J, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63 (12): 1140-7
4. Newcorn J. Efficacy trials of atomoxetine for ADHD in children, adolescents and adults [abstract 40B]. 49th Annual Meeting American Academy of Child and Adolescent Psychiatry; 2002 Oct 25: San Francisco (CA): 66
5. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112-20
6. Biederman J, Faraone SV, Mick E, et al. Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources. J Am Acad Child Adolesc Psychiatry 1999; 38 (8): 966-75
7. Wernicke JF, Allen AJ, Faries D, et al. Safety of tomoxetine in clinical trials [abstract]. In: 56th Society of Biological Psychiatry Annual Meeting; 2001 May 3-5; New Orleans (LA). Biol Psychiatry 2001; 49 (8 Suppl.): 159S
8. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502-8
9. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343 (25): 1833-8
10. Bravo EL. Phenylpropanolamine and other over-the-counter vasoactive compounds. Hypertension 1988; 11 (3 Pt 2): II7-10
11. Angrist B, Sanfilipo M, Wolkin A. Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol. Clin Neuropharmacol 2001; 24 (3): 139-44
12. Brauer LH, Ambre J, De Wit H. Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. J Clin Psychopharmacol 1996; 16 (1): 72-6
13. National High Blood Pressure Education Program Working Group. Update on the task force report (1987) on high blood pressure in children and adolescents: a working group report from the national high blood pressure education program. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute; 1996 Sep. Report no.: 96-3790
14. Committee for Proprietary Medicinal Products. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; 1997 Dec 17. Report no.: CPMP/986/96
15. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72 (6): 17B-22B